Giulia KennedyPhD
JAMA Surgery · 2018

Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules

Kepal N. Patel, Trevor E. Angell, Joshua Babiarz, Neil M. Barth, Thomas Blevins, Quan-Yang Duh, Ronald A. Ghossein, R. Mack Harrell, Jing Huang, Giulia C. Kennedy, Su Yeon Kim, Richard T. Kloos, Virginia A. LiVolsi, Gregory W. Randolph, Peter M. Sadow, Michael H. Shanik, Julie A. Sosa, S. Thomas Traweek, P. Sean Walsh, Duncan Whitney, Michael W. Yeh, Paul W. Ladenson

Co-authorverifiedThyroid nodule genomic classificationMachine learning for clinical diagnostics
Journal
JAMA Surgery · vol. 153 · no. 9 · pp. 817-824
Published
1 Sep 2018

Synopsis

The pivotal blinded validation of the second-generation Afirma Genomic Sequencing Classifier on 191 Bethesda III/IV indeterminate fine-needle aspirates from 49 U.S. centres, collected June 2009 to December 2010 from patients who all had surgery without genomic information. The classifier had 91% sensitivity (95% CI 79-98) and identified at least one third more benign thyroid nodules among those deemed indeterminate by cytopathology than the original Afirma test. Kennedy is tenth of twenty-two authors.

In the career genome

  • VeracyteChapter 06 · Strand A · Company
    Veracyte, Inc.

    Veracyte

    Chief Scientific Officer; Chief Medical Officer from 2018; Global Chief Scientific Officer and Chief Medical Officer from 2022

    APR 2008 – DEC 2022
  • VeracyteChapter 10 · Strand B · Publication
    Veracyte, Inc.

    Afirma GSC and the Xpression Atlas

    Chief Scientific Officer and Chief Medical Officer, Veracyte

    MAY 2017 – SEP 2022